Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?  by Bonecker, Simone et al.
rev bras hematol hemoter. 2 0 1 5;3  7(2):142–143
www.rbhh.org
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
Letter to the Editor
Is the  BCR-ABL/GUSB  transcript  level  at diagnosis
an early  predictive  marker  for chronic  myeloid
 ileukemia patients  treated  with
Dear Editor,
The development of the ﬁrst target-speciﬁc tyrosine kinase
inhibitor (TKI) and its introduction in the clinical practice rad-
ically changed chronic myeloid leukemia (CML) treatment.
Monitoring therapeutic response to TKIs is a critical step in
the management of CML.1
Recently, several follow-up studies upon which the Euro-
pean Leukemia Net 2013 (ELN) recommendations were based,
pointed to the importance of early clearance of leukemic cells
as demonstrated by molecular methods. Attaining a BCR-
ABLIS transcript level ≤10% three months after initial imatinib
mesylate (IM) treatment was found to be associated with
a favorable outcome, including longer progression-free (PFS)
and overall survival (OS), and higher probability of achieving
complete cytogenetic response (CCyR) and major molecular
response (MMR).1
Quantiﬁcation of the BCR-ABL transcript level reﬂects
leukemic burden, and is carried out by quantitative real-time
polymerase chain reaction (RQ-PCR). Molecular response is
based on the ratio of BCR-ABL transcript levels and a con-
trol gene. Results are expressed according to an international
scale (IS) assigned to every patient at diagnosis, which is equal
to 100% of BCR-ABL/control gene transcripts, regardless of
the absolute amount of BCR-ABL transcripts. Thus, the actual
leukemic burden of patients at diagnosis is not taken into
account.2
An ideal control gene would be expected to be uniformly
expressed in different cell types regardless of its proliferative
status as well as be unaffected by therapeutic regimens, con-
stant between individuals and expressed at a level similar to
BCR-ABL. In fact, this control gene does not exist, and BCR
and ABL are the most widely used control genes for quanti-
fying BCR-ABL transcripts, mainly due to historical reasons.
However, both BCR and ABL control genes do not show linear-
ity with BCR-ABL transcript levels above 10% contrary to the
GUSB gene that is not affected by high-level distortions which
allow for better estimations of the BCR-ABL transcript level at
diagnosis.3
In this study, the BCR-ABL transcript levels of 31 CML
patients under IM treatment were analyzed by RQ-PCR inmatinib?
respect to the ABL and GUSB control genes at diagnosis and
after three months of therapy. These patients were followed
up for at least 24 months. The median BCR-ABL1/ABL and
BCR-ABL1/GUSB transcript levels at diagnosis were 87.84%
(range: 16.24–184.4) and 29.8% (range: 5.76–216.9), respectively.
At three months, the median BCR-ABL/ABL transcript level
was 7.14 (range: 0.053–307) whereas the median BCR-ABL/GUS
transcript level was 21.94 (range: 0.19–85.16). Patients were
classiﬁed as optimal responders or non-responders (failure
of response) according to a BCR-ABL1IS transcript level ≤0.1%
and >0.1% at 12 months. In responders, the median BCR-
ABL/ABL and BCR-ABL/GUS transcript levels at diagnosis were
68.13% (range: 26.8–99.29) and 23.77 (range: 8.2–62.97), respec-
tively while in non-responders these levels were 86.10 (range:
30.87–96.11) and 40.92 (range: 17.21–96.85).
The median BCR-ABL/ABL of responders and non-
responders at diagnosis was not signiﬁcantly different
(p-value = 0.89) while the median BCR-ABL/GUS between
responders and non-responders at diagnosis was signiﬁ-
cantly different (p-value <0.001) indicating that, unlike ABL,
GUS levels are capable of discriminating responders from
non-responders (Figure 1). The median transcript level of BCR-
ABL/GUS of responders at diagnosis was 28.38% which might
be considered a threshold for early discrimination as patients
with levels under 28.38% were less likely to achieve MMR  at 12
months (p-value <0.05).
Comparisons of transcript levels three months after ini-
tiating IM treatment were also carried out considering a
BCR-ABL/control geneIS threshold of ≤10% as discriminative
of responders vs. non-responders. In patients considered to be
optimal responders, the median of the transcripts estimated
with any control gene was below 10%, as expected according to
previous reports. We  did not observe a statistically signiﬁcant
difference between ABL and GUS control genes (p-value = 0.19)
in either responders or non-responders (p = 0.41), indicating
that at the three month time point, both genes can be equally
used as predictive biomarkers, showing signiﬁcant differences
between responders and non-responders (p-value = 0.003 for
GUS and p-value = 0.01 for ABL; Figure 1).
The current availability of several therapeutic modalities
for CML  treatment requires early predictive parameters for
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Figure 1 – The median levels of the transcripts considering
both control genes (GUS and ABL) at diagnosis and after
three months on imatinib (IM) as ﬁrst line therapy. Patients
are discriminated as responders or non-responders
according to their response at 12 months according to the
ELN guidelines. The medians of the transcripts were
compared by Mann–Whitney unpaired two-tailed test. At
diagnosis: *p-value < 0.001. At 3 months: *p-value = 0.01;
**p-value = 0.003. Resp = responders; No
Resp = non-responders; ns = non-signiﬁcant.
f
m
a
m
a
g
a
r
h
a
<
v
s
l
r
1
2
3
4uture response. In this study, we  used parameters recom-
ended for identifying optimal response (with BCR-ABLIS ≤10
t three months and ≤0.1 at 12 months after initiating treat-
ent). However, BCR-ABL/ABL transcript levels cannot be used
s predictive estimates due to the lack of linearity of the ABL
ene in assessing leukemic burden at levels above 10% and
ctual levels of BCR-ABL transcripts at diagnosis can be accu-
ately estimated with GUS as the control gene. We  found that
igh levels of BCR-ABL/GUS at diagnosis were associated with
 lower probability of achieving optimal response (p-value
0.001) and low rates of CyCR after 12 months of IM therapy (p-
alue <0.001). These ﬁndings coincided with Vigneri et al.4 who
howed that high rates of BCR-ABL/GUS were associated with a
ow probability of event-free survival (p-value <0.001) and PFS 1 5;3  7(2):142–143 143
(p-value = 0.01). As expected, the loss of ABL linearity result-
ing in transcript quantiﬁcation with high levels of leukemic
burden indicated that ABL, if used as the control gene at diag-
nosis, would not provide predictive estimates. Conversely, the
use of GUS as the control gene allows for a reliable prediction
of therapeutic response based on BCR-ABL transcript levels at
diagnosis.
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